drug

ER-100

Phase 1updated 3mo ago

by Life Biosciences Inc.

Phase 1

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying ER-100

phase1Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)recruitingn=18

News(1)

Fierce Biotech Fundraising Tracker '26: Vaderis nets $152M series B; Epicrispr adds $90M
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
fiercebiotech · 7mo ago

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

ER-100

Phase 1updated 3mo ago

by Life Biosciences Inc.

Phase 1

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying ER-100

phase1Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)recruitingn=18

News(1)

Fierce Biotech Fundraising Tracker '26: Vaderis nets $152M series B; Epicrispr adds $90M
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
fiercebiotech · 7mo ago

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

ER-100

all catalysts(0)

Trials studying ER-100

News(1)

Report a data issue

comments(0)

ER-100

all catalysts(0)

Trials studying ER-100

News(1)

Report a data issue

comments(0)